Power3 Medical Products, Inc. (PWRM.OB)
PWRM announced recently that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease, said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.
We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment, said Helen R. Park, MS, Chief Executive Officer of PWRM, and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.
We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions, added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
Interactive Brokers Group, Inc. (NASDAQ:IBKR) an automated global electronic market maker and broker, recently reported diluted earnings per share of $0.26 for the quarter ended September 30, 2010, compared to diluted earnings per share of $0.20 for the same period in 2009. Net revenues were $299 million and income before income taxes was $162 million for this quarter, compared to net revenues of $272 million and income before income taxes of $133 million for the same period in 2009.
Interactive Brokers Group, Inc. operates as an automated global electronic market maker and broker. It engages in routing orders, and executing and processing trades in securities, futures, and foreign exchange instruments on approximately 80 electronic exchanges and trading venues worldwide. The company provides bid and offer quotations on approximately 600,000 securities and futures products listed on electronic exchanges. It also offers order management, trade execution, and portfolio management platform to access financial markets, and trade in multiple asset classes, such as stocks, options, futures, foreign exchange, bonds, and mutual funds.
Incyte Corporation (Nasdaq:INCY) announced recently that it has earned a $19 million dollar milestone payment from Eli Lilly and Company (NYSE:LLY - News) based on the initiation of a Phase IIb clinical trial evaluating INCB28050 for the treatment of rheumatoid arthritis. This trial is being conducted by Eli Lilly as part of the exclusive worldwide license and collaboration agreement for Incyte's novel, oral, JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104.
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and for chronic inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase II trial for polycythemia vera/essential thrombocythemia; Phase I/II trial to treat other hematologic tumors; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase II clinical trial product for rheumatoid arthritis; INCB28060, a Phase I product for solid cancers; INCB7839, a Phase II product for breast cancer; INCB24360, an IND cleared product for oncology; and INCB13739, a Phase IIb product to treat type 2 diabetes. I
NextEra Energy, Inc. (NYSE:NEE) recently announced it plans to report third quarter 2010 financial results in a news release to be issued before the opening of the New York Stock Exchange on Friday, Oct. 29, 2010.
NextEra Energy, Inc., through its subsidiaries, engages in the generation, transmission, distribution, and sale of electric energy in the United States and Canada. The company, through its subsidiary, NextEra Energy Resources, LLC, involves in the generation of renewable energy from the wind and sun in North America. It operates emissions-free nuclear power generation facilities in New Hampshire, Iowa, and Wisconsin as part of the NextEra Energy nuclear fleet. The company?s other subsidiary, Florida Power & Light Company, serves approximately 4.5 million residential, commercial, and industrial customers in Florida. I
Cytec Industries Inc. (NYSE:CYT) reported recently that the company's Board of Directors declared a regular quarterly cash dividend of $.0125 per share on the common stock of the company, payable on November 26, 2010 to shareholders of record as of November 10, 2010.
Cytec Industries Inc., a specialty chemicals and materials company, engages in the development, manufacture, and sale of chemical products worldwide. The company?s Coating Resins segment offers radcure resins, including oligomers, monomers, and photo-initiators; powder coating resins, such as conventional and ultraviolet powder coating resins; and liquid coating resins comprising waterborne resins, solventborne resins, amino cross-linkers, and urethane resins. Its Additive Technologies segment provides polymer additives consisting of ultraviolet light stabilizers and absorbers, high performance antioxidants, and antistatic agents; and specialty additives, including surfactants, specialty monomers, resin amines, and PTZ Phenothiazine (acrylic acid stabilizers).
Sign-Up For Free Hot Stock Alerts At http://stockhottips.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. StockHotTips.com.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stockhottips.com/disclaimer)Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).